| Trial-Results center | |||
| Clinical trial results database in Heart and vessels |
 Feedback
 Home
|
Systematic review and meta-analysis
This trial is included in the following systematic reviews and meta-analyses:
cardiovascular prevention
-
cholesterol lowering intervention
-
diabetic patients
cardiovascular prevention
-
cholesterol lowering intervention
-
all chronical situations
cardiovascular prevention
-
HDL increasing drugs
-
all type of patients
Related trials
ACCELERATE, 2015 - evacetrapib vs placebo
IMPROVE-IT, 2014 - ezetimibe vs control
dal-OUTCOMES, 2012 - dalcetrapib vs placebo
dal-VESSEL, 2011 - dalcetrapib vs placebo
AIM-HIGH, 2011 - niacin vs placebo (on top statin)
SHARP, 2010 - ezetimibe+simvastatin vs placebo
ARBITER-HALTS 6, 2010 - ezetimibe vs niacin
SEARCH, 2010 - simvastatin high dose vs simvastatin
ACCORD lipid, 2010 - fenofibrate vs placebo (on top simvastatine)
ACCORD lipid (subgroup Eye study), 2010 - fenofibrate vs placebo (on top simvastatine)
DEFINE, 2010 - anacetrapib vs placebo
ARBITER 6-HALTS (niacin vs ezetimibe), 2009 - niacin vs ezetimibe
ARBITER 2, 2009 - niacin vs placebo (on top statin)
Emmerich, 2009 - etofibrate vs placebo
Oxford Niaspan Study, 2009 - niacin vs placebo (on top statin)
JUPITER, 2008 - rosuvastatin vs placebo
SANDS, 2008 - aggressive treatment vs standard teatment
Tuttle, 2008 - low fat diet vs mediterranean-style diet
GISSI-HF rosuvastatine, 2008 - rosuvastatin vs placebo
ILLUSTRATE, 2007 - torcetrapib vs placebo (on top of atorvastatin)
SAGE, 2007 - atorvastatin high dose vs pravastatin
Krum, 2007 - rosuvastatin vs placebo
RADIANCE 2, 2007 - torcetrapib vs placebo (on top of atorvastatin)
ILLUMINATE, 2007 - torcetrapib vs placebo (on top of atorvastatin)
See also:
| Emmerich study, 2009 | TRC10782 |
 download pdf:
etofibrate
|
cholesterol lowering intervention for cardiovascular prevention
|
Treatments
| Studied treatment |
etofibrate 1g/j
|
| Control treatment |
placebo
|
Patients
| Patients | patients with type 2 diabetes mellitus and concomitant diabetic retinopathy | ||||||||
| Baseline characteristics |
|
Method and design
| Randomized effectives | NA / NA (studied vs. control) |
| Design | Parallel groups |
| Blinding | double-blind |
| Follow-up duration | 12 months |
| Geographic area | Germany |
| Primary endpoint | not defined |
Results
No results available for this trial - no clinical endpoint reported
Meta-analysis of all similar trials:
cholesterol lowering intervention in cardiovascular prevention for diabetic patients
cholesterol lowering intervention in cardiovascular prevention for all chronical situations
HDL increasing drugs in cardiovascular prevention for all type of patients
Reference(s)
| TrialResults-center ID | TRC10782 |
| Trials register # | NA |
-
Emmerich KH, Poritis N, Stelmane I, Klindzane M, Erbler H, Goldsteine J, G�rtelmeyer R.
[Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy].
Klin Monbl Augenheilkd 2009;226:561-7
- 10.1055/s-0028-1109516
Pubmed
|
Hubmed
| Fulltext
(c) 2004-2016 TrialResults-center - All Rights Reserved
Tweet this
Facebook
notify a friend